Sp471
PLASTICITY AND HOW VIRAL-LIKE DOUBLE-STRANDED RNA INDUCES GASTRIC PALIGENOSIS AND METAPLASIA
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
This session will feature speakers who will examine cellular plasticity in the gastrointestinal tract and its role in regeneration. The session will focus on epithelial cell responses to pathogens. The ession will explore state of the art organoid studies and how these are being implemented to study cellular plasticity in gastrointestinal diseases.
This session will feature speakers who will examine cellular plasticity in the gastrointestinal tract and its role in regeneration. The session will focus on epithelial cell responses to pathogens. The ession will explore state of the art organoid studies and how these are being implemented to study cellular plasticity in gastrointestinal diseases.
Presenter
Washington University School of Medicine
Tracks
Related Products
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
